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• Sildenafil decreased fetal blood pressure and placent l blood flow in hypoxemia. 3 
• Nifedipine did not disturb placental blood flow in fetal hypoxemia. 4 






























Introduction: We hypothesized that nifedipine and sildenafil would have no detrimental effects on 3 
placental hemodynamics and gas exchange under fetal hypoxemia.  4 
Methods: In 33 chronically instrumented fetal sheep, placental volume blood flow (QPlac) and 5 
umbilical artery (UA) vascular impedance were measured by Doppler ultrasonography. Fetal 6 
carotid artery blood pressure and blood gas values were monitored. After baseline data collection, 7 
maternal and fetal hypoxemia were induced. Following hypoxemia phase data collection, 12 fetuses 8 
received sildenafil and 9 fetuses nifedipine infusion, and 12 fetuses served as controls receiving 9 
saline infusion. Data were collected 30 and 120 minutes after infusion was started. Then maternal 10 
oxygenation was normalized and normoxemia phase data were collected, while infusion was 11 
continued. 12 
Results: Hypoxemia significantly decreased fetal pO2 and blood pressure. In the sildenafil group at 13 
30- and 120-minutes hypoxemia + infusion phases, fetal blood pressure and QPlac were significantly 14 
lower and pCO2 higher than at baseline without returning to baseline level at normoxemia + 15 
infusion phase. In hypoxemia, nifedipine did not affect fetal blood pressure or placental 16 
hemodynamics. Both in the sildenafil and nifedipine groups, fetal pO2 remained significantly lower 17 
at normoxemia + infusion phase than in the control g up. Umbilical artery vascular impedance did 18 
not change during the experiment. 19 
Discussion: In fetal hypoxemia, sildenafil had detrimental effects on placental hemodynamics that 20 
disturbed placental gas exchange. Nifedipine did not alter placental hemodynamics in hypoxemia 21 
but disturbed placental gas exchange upon returning to ormoxemia. Umbilical artery vascular 22 
impedance did not reflect alterations in placental hemodynamics.  23 




Abbreviations: QPlac, placental volume blood flow; UA, umbilical artery; PI, pulsatility index; UV, 1 
umbilical venous; Rplac, placental vascular resistance; MAP, mean arterial pessure: LMM, Linear 2 
Mixed Model  3 
 4 
1. Introduction 5 
In pregnancies complicated by maternal hypertensive disorder, antihypertensive medication is often 6 
indicated. Calcium channel blockers, i.e. nifedipine, are commonly used in pregnancy to control 7 
maternal blood pressure. In addition, calcium channel blockers have a tocolytic effect on uterine 8 
smooth muscle and therefore they are widely used to delay delivery in preterm labor 1. It has been 9 
shown that nifedipine does not lower fetal blood pressure 2. However, there is some evidence that 10 
nifedipine could impair uterine blood flow, potentially even resulting in fetal hypoxemia and 11 
acidemia 3. In human pregnancies, studies have shown that maternal  nifedipine administration 12 
either does not change uterine artery hemodynamics or may cause a short-term decrease in uterine 13 
artery vascular impedance, while umbilical artery vascular impedance is unaffected 4, 5.14 
Recently sildenafil citrate (sildenafil), an inhibitor of phosphodiesterase-5, has gained a lot of 15 
interest, especially as a potential treatment in pregnancies complicated by early onset severe fetal 16 
growth restriction and placental insufficiency. Sildenafil has shown promise in studies of fetal 17 
growth restriction, preeclampsia, as well as in animal studies 6-13. However, recent randomized trials 18 
revealed disappointing results suggesting that sildenafil does not prolong pregnancy or improve 19 
pregnancy outcomes in severe early-onset fetal growth restriction 14, 15. There is even alarming 20 
evidence that maternally administered sildenafil could be harmful to the newborns by increasing the 21 
incidence of persistent pulmonary hypertension 16.  22 
Both nifedipine 17 and sildenafil 18 cross the placenta with fetal concentrations close t  those 23 




placental insufficiency and suboptimal gas exchange exposing the fetus to hypoxemia. Therefore, 1 
we developed a fetal sheep model to investigate the ffects of nifedipine and sildenafil on placental 2 
hemodynamics when fetus is hypoxemic. We hypothesized that nifedipine and sildenafil would not 3 
detrimentally affect placental hemodynamics and gas exchange under hypoxemic conditions. The 4 
specific aims of the present study were to explore the effects of nifedipine and sildenafil on 1) fetal 5 
arterial blood pressure and placental volume blood flow, 2) fetal arterial blood gas values, and 3) 6 
umbilical artery blood flow velocity waveform pattern. 7 
 8 
2. Materials and Methods 9 
 10 
The study protocol was reviewed and approved by the National Animal Experiment Board of 11 
Finland (ESAVI/1007/04.10.07/ 2014). The animal care nd experimental procedures were 12 
conducted according to the national legislation 19 and the EU Directive 2010/63/EU 20. A total of 33 13 
sheep of Finnish breed with time-dated pregnancies were included in this study.  14 
2.1 Surgical protocol 15 
Sheep underwent surgery at 115-129 gestational days (term 145 days) for fetal instrumentation 16 
under general anesthesia that was induced with intravenous Propofol (4–7 mg/kg) and maintained 17 
with isoflurane (1.5–2.5%) in an oxygen–air mixture delivered via an endotracheal tube. Fentanyl 18 
(0.05–0.15 mg) was given as intravenous boluses when required. After laparotomy, the fetal head 19 
and neck were delivered through a small hysterotomy incision. Polyvinyl catheters were introduced 20 
into the internal jugular vein and the carotid artery. A 3-lead 28-gauge silver coated copper 21 
electrocardiogram wire (New England Wire Tech., Lisbon, NH) was inserted subcutaneously on the 22 
fetal chest. A polyvinyl catheter was placed in the amniotic cavity to monitor intra-amniotic 23 
pressure. The lost amniotic fluid was replaced with arm 0,9 % saline solution.  All incisions were 24 




catheters and wires were tunnelled to a pouch on the ewe’s flank. Post-operative pain was 1 
controlled with oxycodone given via epidural catheter that was placed to the ewe before the surgery. 2 
2.2 Experimental protocol 3 
Following a 4-5-day recovery period, at 119-133 gestational days, the experiments were performed 4 
under general anesthesia induced with propofol and maintained by isoflurane in an oxygen/air 5 
mixture. A 16-gauge polyurethane catheter was inserted into the maternal femoral artery. 6 
Anesthesia was titrated to minimize its effect on maternal heart rate and blood pressure and allow 7 
for ultrasound examination without discomfort. The ewe was placed supine with a right lateral tilt 8 
and allowed to stabilize for 30 minutes before obtaining the baseline measurements. Thereafter, the 9 
ewe was connected to a re-breathing circuit to induce maternal and fetal hypoxemia. Maternal FiO2 10 
was reduced to reach the oxygen saturation level of 80%. This was verified by maternal arterial 11 
blood gas values. Hypoxemia phase data (hypoxemia) were collected 30 minutes after desired 12 
maternal oxygen saturation level was reached. After hypoxemia data collection, 12 fetuses were 13 
allocated to receive sildenafil infusion into the internal jugular vein (sildenafil citrate 0.8mg/ml) that 14 
was diluted 1:1 in saline and infused at a rate of 2.5ml/h (1.0mg/h). The sildenafil dose was selected 15 
from the study by Jaillard et al 22. Nine fetuses were allocated to receive nifedipine infusion at a rate 16 
of 1.0 ml/h (700 µg/ml) (5 µg/kg/min). The nifedipine dose was based on the studies by Blea et al ² 17 
and Nugent et al 23. The control group consisted of 12 fetuses that receiv d saline infusion, 18 
respectively. Data were collected at 30 (hypoxemia + 30 min) and 120 (hypoxemia + 120 min) 19 
minutes following commencement of infusion. After hypoxemia+120 min infusion data collection 20 
was completed, maternal oxygenation was returned to baseline level while infusion was continued. 21 
Maternal normoxemia was achieved within 1-3 minutes. Recovery phase data collection 22 
(normoxemia + infusion) was started 30 minutes after maternal normoxemia was restored (Figure 23 
1). The infusion time was about 150 minutes in each group, and the calculated total mean dose of 24 




euthanised at the end of the experiment with an intravenous overdose (100 mg/kg) of pentobarbital 1 
sodium to the fetus and ewe. Fetal weights were detrmined postmortem. 2 
2.3 Monitoring protocol 3 
Maternal and fetal blood pressures were continuously monitored with disposable pressure 4 
transducers (DT-XX, Ohmeda, Hatfield, UK). Fetal arterial and venous blood pressures were 5 
referenced to intra-amniotic pressure. Heart rates w re determined from the arterial pressure 6 
waveforms. Fetal electrocardiogram leads were connected to the ultrasound equipment. Maternal 7 
and fetal blood gas values were corrected to 39°C and analyzed at each study point using an Abbot 8 
i-Stat 1 arterial blood gas analyzer (i-Stat, East Windsor, NJ, USA). 9 
Doppler ultrasonography of placental hemodynamics wa performed at the end of each phase by a 10 
single investigator (J.R.) using the Vivid 7 Dimension ultrasound system (GE Vingmed Ultrasound, 11 
Horten, Norway) with a 10 MHz-phased array transducer. The high-pass filter was set at minimum, 12 
and the angle of insonation was kept below 15 degrees. Umbilical artery pulsatility index (PI) 13 
values were calculated ([peak systolic velocity – end diastolic velocity]/ime-averaged maximum 14 
velocity over the cardiac cycle). Three consecutive cardiac cycles were measured, and the mean 15 
value was used for further analysis. Placental volume blood flow (Qplac) was estimated by 16 
calculating umbilical venous (UV) volume blood flow as follows: 0,5 × UV maximum velocity 17 
(cm/s) ×π (UV diameter (cm)/2) ² ×60. 21 Placental volume blood flow was weight indexed. 18 
Placental vascular resistance (Rplac) was calculated by dividing fetal MAP by Qplac. 19 
2.4 Statistical analysis 20 
 21 
Linear Mixed Model (LMM) was used for repeatedly measured data. Phase of the experiment and 22 
treatment versus saline were included as fixed effects, an interaction term, and individual fetus as 23 
random intercept. If LMM showed a significant difference between measurement points (p(time) < 24 




groups was expressed as p(group). The groups may not show similar changes with time (interaction 1 
term). Therefore, this was expressed as p(group*time). Statistical analyses were performed using 2 
SPSS (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 25. Armonk, NY: 3 
IBM Corp.). Data are presented as mean and standard deviation (SD) unless stated otherwise. Two-4 
tailed p value < 0.05 was considered statistically significant. 5 
 6 
3. Results 7 
 8 
The experiments were performed at the mean (SD) gestational age of 128 (2), 126 (5) and 128 (3) 9 
days in the control, nifedipine and sildenafil groups (F=0.88, p=0.42). Maternal weight was 10 
comparable between the groups. Maternal heart rate and blood pressures did not differ between the 11 
groups during the experiment (data not shown). Mean (SD) fetal weight was 2.44 (0.28), 2.52 (0.24) 12 
and 2.38 (0.34) kg in the control, nifedipine and sil enafil groups (F=0.58, p=0.56).  13 
During hypoxemia phase, fetal pO2 and mean arterial pressure (MAP) decreased significa tly 14 
compared to baseline with no difference between the groups. Other fetal blood gas values, as well 15 
as placental hemodynamic parameters and UA PI values were comparable to baseline (Tables 1 and 16 
2). 17 
At hypoxemia + 30 min infusion and hypoxemia + 120 min infusion phases, fetal MAP and weight- 18 
indexed QPlac were significantly lower compared to baseline in the sildenafil group (Table 2, 19 
Figures 2 and 3). Weight-indexed RPlac did not change significantly. Furthermore, fetal pCO2 20 
increased significantly at hypoxemia + 120 min infusion phase in the sildenafil group (Table 1). In 21 
the control and nifedipine groups, fetal MAP, placental hemodynamic parameters and pCO2 22 
remained stable during the hypoxemia + infusion phases. In addition, in each group, fetal pH and 23 




infusion phases with no differences between the groups. Umbilical artery PI values did not change 1 
during the hypoxemia + infusion phases in any of the groups. 2 
During normoxemia + infusion phase, fetal MAP and QPlac remained significantly lower and fetal 3 
pCO2 higher than at baseline in the sildenafil group (Table 2, Figures 2 and 3). In addition, in the 4 
sildenafil group fetal pCO2 was significantly higher than in the control and nifed pine groups. At 5 
normoxemia + infusion phase, fetal pO2 values remained significantly lower in the sildenafil nd 6 
nifedipine groups than in the control group (Table 1). Fetal pH, base excess and lactate values were 7 
lower than at baseline in each group. Umbilical artery PI values and RPlac were comparable to 8 
baseline values with no difference between the groups. 9 
 10 
4. Discussion 11 
In the present study using a chronically instrumented sheep model with intact placental circulation 12 
and fetal hypoxemia, we found that sildenafil, when given directly to the fetus, significantly 13 
decreased fetal arterial blood pressure and placentl volume blood flow that were associated with a 14 
rise in fetal pCO2 indicating abnormal placental perfusion. On the other hand, fetal nifedipine 15 
infusion did not significantly alter placental volume blood flow or fetal arterial blood pressure. 16 
However, during normoxemia + infusion phase fetal pO2 did not return to baseline level in 17 
nifedipine and sildenafil groups. Despite significant changes in fetal blood gas values, placental 18 
volume blood flow and fetal blood pressure in the sildenafil group, umbilical artery vascular 19 
impedance did not reflect any of these alterations. 20 
Both sildenafil and nifedipine cross the placenta and their concentrations in fetal blood are close to 21 
those values in maternal blood. In the present study, we wanted to explore the direct effects of 22 
sildenafil and nifedipine on the fetoplacental circulation rather than those secondary to changes in 23 




during hypoxemia in relevant concentrations 22, 23. Previously, we have shown that fetal sildenafil 1 
infusion does not alter cardiac function or central hemodynamics in hypoxemia 24.  Experimental 2 
studies have shown that umbilicoplacental circulation has no significant autoregulative capacity and 3 
perfusion pressure has a critical role in the maintenance of placental volume blood flow 25. 4 
Therefore, a drop in fetal arterial blood pressure can have a profound detrimental effect on placental 5 
volume blood flow and gas exchange. On the other hand, it has been shown that sildenafil infusion 6 
into the fetal circulation did not affect fetal arterial blood pressure under normoxemic environment 7 
22.  In addition, a previous sheep study with fetal intrauterine growth restriction induced by single 8 
umbilical artery ligation showed that maternally administered sildenafil significantly reduced 9 
uterine blood flow and decreased fetal pO2 as well as arterial blood pressure 
26. We propose that 10 
sildenafil could interfere with hypoxemia induced fetal peripheral chemoreflex causing a drop in 11 
fetal blood pressure and placental volume blood flow. Altogether, evidence from experimental 12 
studies including the present study point out that sildenafil can have significant detrimental effects 13 
on both utero- and umbilicoplacental hemodynamics, even with intact placental circulation.  14 
We did not find any significant change in fetal arterial blood pressure or placental volume blood 15 
flow during nifedipine infusion under fetal hypoxemia. However, during normoxemia + infusion 16 
phase fetal pO2 remained lower than in the control group. Our observations are in agreement with a 17 
study that found only a transient reduction in uteroplacental blood flow with no change in 18 
fetoplacental blood flow by using radioactively-labeled microsphere technique when nifedipine was 19 
administered to the ewe 2. In addition, nifedipine did not alter volume blood flows and vascular 20 
resistances of the fetal organs, except for the adrnal blood flow that increased during nifedipine 21 
administration. However, conflicting results have been reported. Maternal nifedipine infusion has 22 
been shown to increase fetal lung and skeletal muscle blood flow, while blood flow to carcass 23 
decreases, suggesting a redistribution of fetal circulation 27. In addition, significant increases in total 24 




It seems that at least some of these hemodynamic changes are related to nifedipine dose, because 1 
with higher doses also a reduction in uterine blood fl w and fetal arterial oxygen content have been 2 
demonstrated 3. In the present study, nifedipine infusion did notalter fetal blood gas values during 3 
hypoxemia, most likely reflecting mean arterial blood pressure and placental volume blood flow 4 
that were maintained comparable to the control group fetuses. Interestingly in nifedipine group, 5 
upon returning to normoxemia + infusion phase, fetal pO2 did not return to baseline level that was 6 
observed in the control group fetuses. This finding is similar to that published previously 2. The 7 
authors observed fetal acidosis and hypoxia without evident temporal blood flow changes and a 8 
relative lack of maternal hemodynamic changes strongly suggesting that other fetal metabolic 9 
mechanisms could explain this finding. It has been speculated that local discrepancies in placental 10 
metabolism caused by cellular calcium entry blockade or increased fetal oxygen utilization could 11 
lead to decreased arterial oxygen content 2.  12 
Sildenafil and nifedipine had no significant effect on umbilical artery PI values. This agrees with a 13 
study, in which fetal growth restriction was induced by uterine artery embolization 28. In a group 14 
with uterine artery embolization and maternal sildenafil, umbilical artery resistance index values 15 
were comparable to the control group fetuses. In contrast, clinical studies on human pregnancies 16 
complicated by maternal preeclampsia or intrauterine fetal growth restriction have reported 17 
improvement in the umbilical artery blood flow velocity waveform during maternal sildenafil 18 
therapy 6, 8, 9. Our findings with significantly reduced placental vo ume blood flow, disturbed gas 19 
exchange and significant fetal metabolic acidosis combined with unaffected umbilical artery PI 20 
demonstrate the limitations of umbilical artery blood flow velocity waveform to detect significant 21 
changes in placental circulatory physiology.  22 
Our experimental study has several clinical implications. Maternally administered vasoactive agents 23 
can also affect fetal and placental circulatory physiology. Sildenafil has shown some promise in the 24 




when administered during pregnancy could increase the incidence of persistent pulmonary 1 
hypertension in newborns 16. We designed this study to explore the effects of ildenafil and 2 
nifedipine on placental hemodynamics under hypoxemic conditions. Fetal hypoxemia often 3 
complicates severe placental insufficiency. The observations that sildenafil decreases fetal arterial 4 
blood pressure and placental volume blood flow and disturbs gas exchange are clinically important. 5 
These detrimental alterations occurred even in the presence of histologically unaffected placental 6 
circulation. Placental insufficiency is usually associated with reduced tertiary villous artery 7 
capacity. Furthermore, our study shows that the effcts of vasoactive drugs on placental circulatory 8 
physiology cannot be explored by only investigating umbilical artery vascular impedance.  9 
STRIDER trials conducted in different countries have revealed partially inconsistent results, but 10 
especially concerning possible harmful effects of in utero exposure to sildenafil on newborn 11 
pulmonary circulatory physiology 14, 16. This becomes even more clinically important, because 12 
animal studies suggest that in fetal congenital diaphr gmatic hernia in utero sildenafil improves 13 
lung vasculature 29. However, in fetuses without diaphragmatic hernia sildenafil can reduce 14 
pulmonary vascular branching. Therefore, more understanding about the action of sildenafil in 15 
different pregnancy complications is urgently needed. Furthermore, as our study shows, umbilical 16 
artery blood flow velocity waveform has a limited capacity to reflect changes in the placental 17 
circulatory physiology. Future studies exploring the possible drug effects on placental 18 
hemodynamics should consider the results of the present study.  19 
5. Limitations  20 
The fetuses underwent surgical intervention that could constitute a major stress. However, the 21 
recovery period after surgery is long enough for recov ry of fetal circulatory physiology as 22 
evidenced by normal blood gas values at baseline 30. We performed the experiments under general 23 
anesthesia that could modify fetal cardiovascular ad ptation. There is evidence that cardiovascular 24 




isoflurane anesthesia. Therefore, at reasonable anesthetic depth, and without myocardial or 1 
peripheral cardiovascular disease, the newborn lambcan coordinate neural, endocrine, and local 2 
tissue responses to increase cardiovascular performance in response to hypoxemia 31. There are 3 
some differences in placental circulatory physiology and anatomy between human and sheep 4 
fetuses. However, sheep experiments have provided invaluable information on placental 5 
hemodynamics. Validation studies in sheep fetuses have proven that invasive and Doppler 6 
echocardiographic volume blood flow calculations correlate well 32. The intraobserver variabilities 7 
of Doppler ultrasonographic parameters of fetal sheep cardiovascular hemodynamics are 8 
comparable to those found in human fetuses during the second half of pregnancy 33, 34.  9 
6. Conclusions 10 
Our study shows that in hypoxemic fetus with intact placental circulation, sildenafil had detrimental 11 
effects on placental hemodynamics by decreasing fetal blood pressure and placental volume blood 12 
flow that led to disturbed placental gas exchange. On the other hand, under fetal hypoxemia 13 
nifedipine did not alter placental hemodynamics. However, it disturbed placental gas exchange 14 
when oxygenation was normalized. Umbilical artery vascular impedance did not change despite 15 
significant alterations in placental hemodynamics. 16 
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Table 1. Fetal arterial blood gas parameters 
__________________________________________________________________________________________________________
Values are mean and (SD).  Group p-value indicates th  level of difference between the control (C), nifedipine (N) and sildenafil (S) groups, 
Time p-value indicates the change in measurements over time. Group x time p-value indicates the group x time interaction. *=<0.05 between 
groups in pairwise comparisons, **=<0.005 between groups in pairwise comparisons.  
Parameter Baseline Hypoxemia Group Hypoxemia 
+ 30 min 
infusion 
Hypoxemia 












2.8 (0.6) 1.6 (0.4) 
C 1.5 (0.4) 1.5 (0.2) 2.8 (0.4) 
0.59 0.001 0.030 N 1.6 (0.4) 1.6 (0.5) 2.3 (0.3)* 
S 1.5 (0.3) 1.5 (0.5) 2.1 (0.4)** 
Base excess 
(mmol/l) -1.4 (3.4) 1.9 (3.2) 
C -7.0 (5.1) -10.2 (6.0) -9.0 (3.6) 
0.99 0.001 0.57 N -6.0 (6.1) -8.9 (5.5) -7.3 (4.8) 
S -6.1 (4.6) -11.6 (7.6) -10.6 (7.9) 
pH 
7.29 (0.05) 7.28 (0.05) 
C 7.21 (0.11) 7.15 (0.12) 7.18 (0.06) 
0.54 0.001 0.72 N 7.21 (0.11) 7.14 (0.14) 7.19 (0.10) 
S 7.19 (0.08) 7.06 (0.16) 7.09 (0.16) 
Lactate (mmol/l) 
0.4 (0.2) 0.5 (0.4) 
C 7.7 (3.5) 9.7 (4.0) 9.6 (4.0) 
0.97 0.001 0.59 N 7.5 (2.8) 10.4 (3.4) 10.4 (3.5) 
S 6.4 (3.0) 10.3 (4.0) 10.8 (4.6) 
pCO2 (kPa) 
  
7.0 (1.1) 7.0 (0.8) 







N 7.1 (0.7) 7.8 (1.5) 7.3 (1.0) 




Table 2. Fetal heart rate, blood pressure and placental hemodynamic parameters. 
  
Parameter Baseline Hypoxemia Group Hypoxemia 
+ 30 min 
infusion 
Hypoxemia 











Heart rate (bpm) 
 
171 (27) 168 (27) 







N 156 (22) 158 (32) 159 (28) 
S 159 (20) 150 (42) 138 (35)¤ 
MAP (mmHg) 
 
40 (8) 36 (7) 







N 36 (4) 32 (7) 32 (5) 
S 33 (8) 28 (5) 28 (6)* 
Qplac (ml/min/kg) 
 
85 (34) 73 (33) 







N 64 (28) 62 (25) 64 (32) 
S 55 (20)¤ 52 (13)¤ 55 (20)¤ 
Rplac(mmHg/ 
ml/min / kg) 
 
0.54 (0.22) 0.61 (0.30) 







N 0.75 (0.50) 0.60 (0.25) 0.58 (0.22) 
S 0.69 (0.33) 0.60 (0.15) 0.62 (0.30) 
UA PI 1.6 (1.6) 1.7 (1.0) 
C 2.8 (3.2) 2.4 (1.5) 2.2 (1.3) 
0.08  0.15 0.46 N 1.7 (0.4) 1.7 (0.5) 1.7 (0.5) 




Values are mean (SD).  Group p-value indicates the level of difference between the control (C), nifedipine (N) and sildenafil (S) groups, Time p-
value indicates the change in measurements over tim. Group x time p-value indicates the group x time nt raction. *=<0.05 between groups in 
pairwise comparisons. ¤ (p<0.05) comparison to baseline. MAP, mean arterial pressure; Qplac, placental volume blood flow; Rplac, placental 








Figure 1. Timeline of the experiment 
Figure 2.  Fetal mean arterial pressure (MAP) during the experiment. Data are presented as mean 
(SD).  ¤ Indicates significant difference (p<0.001) to baseline in the sildenafil group. * Indicates 
significant difference between the control and sildenafil groups (p=0.03). 
Figure 3. Weight-indexed placental volume blood flow (Qplac) during the experiment. Data are 





















Day 5      Experiment day Baseline measurements
30 min Hypoxemia measurements
Start of infusion 
60 min Hypoxemia + 30 min infusion measurements
150 min Hypoxemia + 120 min infusion measurements
Normoxemia
180 min 30 min normoxemia + 150 min infusion measurements
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• Sildenafil decreased fetal blood pressure and placental blood flow in hypoxemia. 
• Nifedipine did not disturb placental blood flow in fetal hypoxemia. 
• Umbilical artery vascular impedance did not reflect placental hemodynamic changes. 
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